Address
Ullernchausseen 64
Oslo
0379, Norway
Contact
Bjørn Klem+9292416156
bk@adjutecpharma.com
Website
Resistance enzyme inhibitors
Our products prevent bacterial enzymes from destroying antibiotics
Our inhibitors target beta-lactamases not covered by inhibitors on the market
Technology:
Microorganisms:
Application:
Development stage:
- Antimicrobial compound/strategy
- Infection prevention
- Antimicrobial stewardship
- Microbial diagnostics
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Development
- Research
- Validation
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Joint Venture
- Outsource
- Sell
Funding organisation:
- OTHER / NA
- CARB-X
- FIND
- GARDP
- REPAIR
Infectious disease area:
- UTI
- BSI
- IAI
- STI
- RTI
- GII
- SSTI
- CNSI
- SSI
Geographic origin:
- Eurasia
- North America
- South America
- Africa
- Oceania
A partner must contribute with competence and funding for late-stage clinical development. A partner may also be distributor in certain markets.
Adjutec is a biotech company developing beta-lactamase inhibitor to overcome the alarming increase in antimicrobial resistance.
Adjutec is supporting academic research in the field of new antibiotics
